Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up - 16/08/11
, Bertrand Pierre, MD a, Karim Wahbi, MD a, Bruno Eymard, MD, PhD b, Annick Toutain, MD c, Carole Berard, MD d, Guy Vaksmann, MD e, Simon Weber, MD, PhD a, Henri-Marc Bécane, MD bRésumé |
Background |
Duchenne muscular dystrophy (DMD), an X-linked disorder due to lack of dystrophin, is associated with muscle weakness and myocardial dysfunction. Although preliminary data support the efficacy of angiotensin-converting enzyme inhibitors on left ventricular (LV) function, our aim was to examine the long-term impact of a preventive treatment with perindopril on mortality in children with DMD.
Methods |
Patients with DMD between the ages of 9.5 and 13 years presenting with normal LV ejection fraction were included in this prospective study. They were randomly assigned for 3 years to perindopril, 2 to 4 mg (group 1), or placebo (group 2) in a double-blind protocol, followed by open-label treatment with perindopril for up to 10 years. Survival rate at 10 years in each group is reported.
Results |
There were 28 patients assigned to group 1 and 29 to group 2. Baseline characteristics were similar in both groups. At the end of the 10 years' follow-up period, survival status was available for all included patients: 26 (92.9%) of 28 patients in group 1 were alive at 10 years versus 19 (65.5%) of 29 in group 2 (P = .02). Kaplan-Meier cumulative survival was significantly lower in group 2 than in group 1 (P = .013).
Conclusion |
Early initiation of treatment with perindopril is associated with a lower mortality in patients with DMD with normal LV ejection fraction at study entry.
Le texte complet de cet article est disponible en PDF.Plan
Vol 154 - N° 3
P. 596-602 - septembre 2007 Retour au numéro
Article précédent
- The effects of ?-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis
- Pascal de Groote, Pierre Delour, Frédéric Mouquet, Nicolas Lamblin, Joël Dagorn, Olivier Hennebert, Thierry Le Tourneau, Claude Foucher-Hossein, Christine Verkindère, Christophe Bauters
- Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy
- Pericle Di Napoli, Paolo Di Giovanni, Marta Assunta Gaeta, Giuseppina D'Apolito, Antonio Barsotti
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?